

Addendum

Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation**Javier Molina-Cerrillo¹, Teresa Alonso-Gordoa¹, Alfredo Carrato¹ and Enrique Grande²**¹Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain²MD Anderson Cancer Center, Madrid, Spain**Published:** November 17, 2022**Copyright:** ©2022 Molina-Cerrillo et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** The patient provided written informed consent.Original article: Oncotarget. 2020; 11:2137–2140. <https://doi.org/10.18632/oncotarget.27598>